United States - English - NLM (National Library of Medicine)

par pharmaceutical companies, inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 200 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established. caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating. studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities. therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of non-treatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have n

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 100 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 100 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 200 ug in 5 ml - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.15 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.075 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.05 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.